Spine Stereotactic Radiosurgery: A Critical Evaluation of the Evidence to Guide Clinical Practice
Rupesh KotechaSpine metastases represent a common complication of lung cancer and other cancers, with approximately 40% of patients developing clinically significant spinal metastatic disease and up to 90% developing subclinical micrometastases. […] Read more
Ophthalmologists are beginning to identify common adverse side effects seen in patients with cancer receiving immunotherapy. The IASLC Lung Cancer News spoke with Asim V. Farooq, MD, about how best to care for patients experiencing or susceptible to such toxicities. Dr. Farooq is associate professor of Ophthalmology and Vis... Read more
Ticiana Leal, MD, has moved to Emory University School of Medicine as associate professor and director of the Thoracic Medical Oncology Program in the Department of Hematology and Medical Oncology. […] Read more
In the National Lung Screening Trial, screening with 2 years of annual low-dose computed tomography (LDCT) achieved a 20% decrease in lung cancer mortality in high-risk populations when compared with […] Read more
The eNRGy1 Global Multicenter Registry: NRG1 Fusions as a Hidden Target in Lung Cancer
Stephen Liu+more
Gene fusions involving ALK, ROS1, RET, and NTRK are now established targets in NSCLC, for which highly effective and well-tolerated kinase inhibitors are the preferred initial therapy. A growing body […] Read more
Surgical resection remains the gold standard for patients diagnosed with early-stage lung cancer, and since the early 1990s, video-assisted thoracoscopic surgery (VATS) lobectomy has been acknowledged as an effective – […] Read more
SEPTEMBER 14, 2021—Lurbinectedin received approval from the Therapeutic Goods Administration (TGA) as treatment for patients with metastatic SCLC who experienced disease progression during or after receipt of platinum-based chemotherapy. The […] Read more
SEPTEMBER 14, 2021—Health Canada approved sotorasib for second-line treatment of patients with locally advanced or metastatic NSCLC and a KRAS G12C mutation. A Notice of Compliance with Conditions was granted […] Read more
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
Mario LacoutureMario Lacouture, MD, is director of the Oncodermatology Program at Memorial Sloan Kettering Cancer Center and specializes in the dermatologic side effects of cancer treatment. He is the founder of the SERIES (Skin and Eye Reactions to Inhibitors of EGFR and kinases) Clinic, an interdisciplinary program bringing together pat... Read more
Not all published papers are on equal footing. Read more